COA

IPAMORELIN nothing more. nothing less.

Ipamorelin is a selective growth hormone secretagogue targeting the ghrelin receptor (GHS-R1a). Studied in research involving pulsatile GH release, endocrine signaling, and peptide-receptor selectivity.

Purity >99.60%Form Lyophilized PowderNo Endotoxins

Ships Tomorrow

Order within

10MG $55.00
Pharmacy $165.99 Save 67%
>99.60% Purity
cGMP-Compliant
SAME DAY SHIPPING
US MADE
Quantity Price Per Unit
5 – 9
10+

For research use only — not for human consumption, therapeutic, or diagnostic use. By adding to cart you acknowledge these terms.

Blank. Credentials

Institutional-grade credentials you can verify

Double Validation HPLC + MS
Priority Delivery Fast Shipping
Expert Support US-Based Team
Risk-Free 14-Day Guarantee
Volume Savings Tiered Pricing

About This Compound

Deep technical insights for clinical research

Primary Research Applications

This compound is supplied strictly for in-vitro and preclinical research use only. Primary applications include the areas below.

Growth Hormone Secretion Stimulation

Selectively stimulates growth hormone release from pituitary somatotrophs without affecting ACTH or cortisol secretion.

Gastrointestinal Motility Research

Demonstrates dose-dependent improvement in gastric emptying and reversal of delayed gastrointestinal transit in postoperative models.

Research Community Feedback

"Consistency is paramount in our cellular model testing. Blank's peptides have maintained the tightest purity specs of any RUO vendor we've audited."

Dr. Julian Kessler

Lead Investigator, Biomatrix Labs

"The availability of detailed MS and HPLC data on the product page saved us two days of redundant internal verification. Professional grade synthesis."

Anika S. Singh

Synthetics Quality Control

"Finally, a supplier that doesn't hide behind consumer marketing. Stark, clear, and high-purity. Exactly what a modern lab needs."

Prof. David Emmerich

Applied Peptide Research

Complete The Protocol

Pairs & Supplies

The compounds and tools researchers stack with IPAMORELIN.

AOD-9604

AOD-9604

$65.00
Add to Cart
TESAMORELIN

TESAMORELIN

$95.00
Add to Cart
CJC-1295 / IPAMORELIN

CJC-1295 / IPAMORELIN

$85.00
Add to Cart

Peer-Reviewed Literature

Related Studies

Ipamorelin · 1998

Ipamorelin, the First Selective Growth Hormone Secretagogue

European Journal of Endocrinology

Foundational paper establishing ipamorelin as a selective GHS-R1a agonist. Unlike GHRP-2 and GHRP-6, ipamorelin does not stimulate ACTH or cortisol, making it uniquely selective.

Ipamorelin · 1999

Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Human Volunteers

Pharmaceutical Research

Dose-escalation trial demonstrated ipamorelin produces a GH release episode peaking at 0.67 hours with terminal half-life of 2 hours across five dose levels in healthy male volunteers.

Ipamorelin · 1999

Ipamorelin Induces Longitudinal Bone Growth in Rats

Growth Hormone & IGF Research

Ipamorelin dose-dependently increased longitudinal bone growth rate from 42 to 52 µm/day with pronounced dose-dependent effects on body weight gain in adult female rats.

Ipamorelin · 1998

Ipamorelin, a New Growth-Hormone-Releasing Peptide, Induces Growth Hormone Release via Hypothalamic GHS-R1a in Conscious Rats

Growth Hormone & IGF Research

Ipamorelin demonstrated potent, dose-dependent GH release without affecting ACTH, cortisol, prolactin, FSH, LH, or TSH — establishing it as the most selective growth hormone secretagogue known.

Ipamorelin · 2000

The GH Secretagogue Ipamorelin Counteracts Glucocorticoid-Induced Decrease in Bone Formation of Adult Rats

Growth Hormone & IGF Research

Ipamorelin prevented dexamethasone-induced bone loss in adult rats, maintaining bone formation markers and trabecular bone mineral density through sustained GH/IGF-I axis stimulation.

Ipamorelin · 2007

Acceleration of Postoperative Bowel Recovery by Ipamorelin: A Novel Growth Hormone Secretagogue

Neurogastroenterology & Motility

Phase II trial in patients after abdominal surgery demonstrated ipamorelin significantly accelerated time to first bowel movement and hospital discharge, acting through ghrelin receptor-mediated prokinetic effects.

From the Lab

Related Blog Posts